Rapport Therapeutics, Inc. (RAPP) Financial Statements
Free cash flow over the same period: -$97.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RAPPRapport Therapeutics, Inc.Follow RAPP — free
—
Price chart with a free account
- Market cap
- 1.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Research & development | 60.9 | 94.8 | 136.7 | |
| Operating income | -83.1 | -125.1 | -153.5 | |
| Pre-tax income | -78.3 | -111.5 | -137.2 | |
| Income tax | 0.0 | 0.0 | — | |
| Net income | -78.3 | -111.5 | -137.2 | |
| Diluted EPS ($) | -3.78 | -2.86 | -2.88 | |
| Diluted shares (mn) | 20.7 | 38.9 | — |
USD millions · SEC XBRL
Rapport Therapeutics, Inc. — questions
- What is Rapport Therapeutics, Inc.'s net income?
- -$137.2M over the twelve months to 2026-06-30.
- What is Rapport Therapeutics, Inc.'s free cash flow?
- -$97.1M over the twelve months to 2026-06-30.
- What are Rapport Therapeutics, Inc.'s diluted earnings per share?
- $-2.88 over the twelve months to 2026-06-30.
Every figure on this page comes from Rapport Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.